X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through agreement, Neuraxpharm will focus on the commercialization of Briumvi (ublituximab) in Europe, for the treatment of adults patients with relapsing forms of multiple sclerosis.
Lead Product(s): Ublituximab
Therapeutic Area: Neurology Product Name: Briumvi
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: TG Therapeutics
Deal Size: $645.0 million Upfront Cash: $152.5 million
Deal Type: Agreement February 26, 2024
Details:
Under the agreement, TG Therapeutics will commercialise Briumvi (ublituximab), the first and only anti-CD20 monoclonal antibody approved in the United States and European Union for adult patients with relapsing forms of multiple sclerosis.
Lead Product(s): Ublituximab-xiiy
Therapeutic Area: Neurology Product Name: Briumvi
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: TG Therapeutics
Deal Size: $645.0 million Upfront Cash: $140.0 million
Deal Type: Licensing Agreement August 01, 2023
Details:
The acquisition will strengthen Neuraxpharm's position as a leading company focused on CNS by including 2 product portfolios for CNS disorders, pain and vascular diseases. The CNS portfolio includes Nozinan (levomepromazine maleate), Tranxene, Tiapridal, Dogmatil, Largactil.
Lead Product(s): Levomepromazine Maleate
Therapeutic Area: Psychiatry/Psychology Product Name: Nozinan
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Sanofi
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition February 01, 2023
Details:
Nozinan (levomepromazine) is a neuroleptic with indications in psychiatry and general medicine, particularly in terminal illness. Clinically it is more sedative and more potent than chlorpromazine in management of psychotic conditions and in relief of severe chronic pain.
Lead Product(s): Levomepromazine Maleate
Therapeutic Area: Psychiatry/Psychology Product Name: Nozinan
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Sanofi
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition July 12, 2022
Details:
Having acquired Brain Therapeutics, Neuraxpharm is now able to bring new products to the Greek market including the market-leading product for emergency treatment of children and adolescents with epilepsy, Buccolam®, will be among the products to be offered.
Lead Product(s): Midazolam
Therapeutic Area: Neurology Product Name: Buccolam
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Brain Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition March 08, 2022
Details:
Buccolam (oromucosal midazolam), value-added buccal midazolam indicated for emergency treatment of children and adolescents from 3 months to 18 years with epilepsy suffering from prolonged acute convulsive seizures.
Lead Product(s): Midazolam
Therapeutic Area: Neurology Product Name: Buccolam
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 12, 2021
Details:
The Permira funds will support the management’s vision of becoming the leading CNS-focused specialty pharmaceutical platform in Europe through driving the commercialization of Neuraxpharm’s attractive new product pipeline and support further its expansion internationally.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Permira Funds
Deal Size: $1,880.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition September 22, 2020
Details:
Buccolam® (Midazolam), fits perfectly within Neuraxpharm’s portfolio, strengthening its position as the European CNS specialist in several European countries, and offers the opportunity to expand the commercial footprint, including into the Nordics and Ireland.
Lead Product(s): Midazolam
Therapeutic Area: Neurology Product Name: Buccolam
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Takeda Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition September 14, 2020
Details:
The agreement, which anchors a previous MOU entered by the companies, includes exclusivity for Panaxia products, as well as an option for scaling the distribution to additional countries, also including further major European countries.
Lead Product(s): Cannabis products
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Panaxia
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 22, 2020
Details:
Ansiolin® (diazepam) is a benzodiazepine indicated to treat anxiety and other somatic or psychiatric conditions associated to anxiety syndrome, while it is also indicated for insomnia.
Lead Product(s): Diazepam
Therapeutic Area: Psychiatry/Psychology Product Name: Ansiolin
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Almirall
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition June 26, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
